FLJ37396: A Transmembrane Protein for Targeted Therapies (G100996634)

Target Name: Transmembrane protein FLJ37396

NCBI ID: G100996634

Transmembrane protein FLJ37396

Other Name(s): LOC100996634

FLJ37396: A Transmembrane Protein for Targeted Therapies

FLJ37396, a member of the Kinesin-67 family, is a transmembrane protein that has been identified as a potential drug target and biomarker. This protein plays a crucial role in the regulation of cell signaling pathways, including the T-cell receptor signaling pathway. FLJ37396 has been shown to interact with multiple intracellular signaling molecules, including T-cell receptor tyrosine kinase (TK), leading to the regulation of immune cell function and cell survival.

The T-cell receptor signaling pathway is a critical pathway involved in the regulation of immune cell function and the generation of diverse immune responses. T-cells are a crucial source of immunity against infections and cancer, and their regulation by FLJ37396 is critical for the development and maintenance of a healthy immune system.

FLJ37396 is a protein that has been shown to interact with multiple intracellular signaling molecules, including T-cell receptor tyrosine kinase (TK). This interaction between FLJ37396 and TK leads to the regulation of T-cell cell function and cell survival.

The Importance of FLJ37396

The regulation of T-cell cell function by FLJ37396 is critical for the development and maintenance of a healthy immune system. T-cells are a crucial source of immunity against infections and cancer, and their regulation by FLJ37396 is critical for the development and maintenance of a healthy immune system.

FLJ37396 plays a crucial role in the regulation of the T-cell receptor signaling pathway. This protein has been shown to interact with multiple intracellular signaling molecules, including T-cell receptor tyrosine kinase (TK). This interaction between FLJ37396 and TK leads to the regulation of T-cell cell function and cell survival.

The T-cell receptor signaling pathway is a critical pathway involved in the regulation of immune cell function and the generation of diverse immune responses. This pathway is critical for the development and maintenance of a healthy immune system, and FLJ37396 plays a crucial role in this process.

Drug Targeting and Biomarker

FLJ37396 has the potential to be a drug target for the treatment of various diseases, including cancer and autoimmune disorders. The regulation of T-cell cell function by FLJ37396 makes it an attractive target for the development of anti-cancer and anti-inflammatory drugs.

FLJ37396 has also been shown to be a potential biomarker for the diagnosis and prognosis of cancer. The regulation of T-cell cell function by FLJ37396 is critical for the development and maintenance of a healthy immune system, which is a crucial factor in the regulation of cancer progression.

Conclusion

FLJ37396 is a transmembrane protein that has been shown to interact with multiple intracellular signaling molecules, including T-cell receptor tyrosine kinase (TK). This interaction between FLJ37396 and TK leads to the regulation of T-cell cell function and cell survival. With its potential as a drug target and biomarker, FLJ37396 is an attractive target for the development of anti-cancer and anti-inflammatory drugs.

Protein Name: Transmembrane Protein FLJ37396

The "Transmembrane protein FLJ37396 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Transmembrane protein FLJ37396 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets